Paper4606353
Colchicine therapy for familial mediterranean fever. A double-blind trial.
Dinarello CA and 4 others. N Engl J Med, 1974. Cited by 244 papers, by iCite.
Cite this record
ConductScience Library. Colchicine therapy for familial mediterranean fever. A double-blind trial. Papers, record 4606353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4606353
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colchicine | Major topic |
| Familial Mediterranean Fever | Major topic |
| Adult | |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Humans | |
| Placebos | |
| Tablets | |
| Time Factors |
Source PubMed
Cited by103
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 244 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42399078 | Beyond genotype: clustering analysis highlights clinical heterogeneity in paediatric familial Mediterranean fever. | RMD Open | 2026 | https://conductscience.org/library/papers/42399078 | PubMed |
| 42270889 | Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort. | Paediatr Drugs | 2026 | https://conductscience.org/library/papers/42270889 | PubMed |
| 42018733 | Amyloidosis secondary to familial Mediterranean fever: machine learning-based prediction models. | Rheumatology (Oxford) | 2026 | https://conductscience.org/library/papers/42018733 | PubMed |
| 41917006 | Adult patients with autoinflammation of unknown origin partially phenocopy the immune presentation of Still's disease. | Nat Commun | 2026 | https://conductscience.org/library/papers/41917006 | PubMed |
| 41789090 | Clinical, immunological characterisation and treatment response of patients with syndrome of undifferentiated recurrent fever in Chinese children and adolescents: a single-centre cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/41789090 | PubMed |
| 41130274 | Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease. | Thromb Haemost | 2026 | https://conductscience.org/library/papers/41130274 | PubMed |
| 40248220 | High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs). | RSC Adv | 2025 | https://conductscience.org/library/papers/40248220 | PubMed |
| 40178516 | Neuroprotective role of Hippo signaling by microtubule stability control in Caenorhabditis elegans. | Elife | 2025 | https://conductscience.org/library/papers/40178516 | PubMed |
| 40108720 | The needed daily dose of colchicine in patients with Familial Mediterranean Fever may be higher in women: a study on behalf of the JIR cohort. | Arthritis Res Ther | 2025 | https://conductscience.org/library/papers/40108720 | PubMed |
| 39912853 | [Colchicine-Phoenix from the ashes]. | Wien Klin Wochenschr | 2025 | https://conductscience.org/library/papers/39912853 | PubMed |
| 39132307 | A narrative review on the role of cytokines in the pathogenesis and treatment of familial Mediterranean fever: an emphasis on pediatric cases. | Front Pediatr | 2024 | https://conductscience.org/library/papers/39132307 | PubMed |
| 38511324 | Colchicine's Role in Cardiovascular Disease Management. | Arterioscler Thromb Vasc Biol | 2024 | https://conductscience.org/library/papers/38511324 | PubMed |
| 38129719 | Recent Insights in Pyrin Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-Associated Autoinflammatory Syndromes. | J Clin Immunol | 2023 | https://conductscience.org/library/papers/38129719 | PubMed |
| 37658934 | The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever. | Clin Rheumatol | 2024 | https://conductscience.org/library/papers/37658934 | PubMed |
| 37298536 | An Update on Familial Mediterranean Fever. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37298536 | PubMed |
| 36656466 | Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation. | Inflammation | 2023 | https://conductscience.org/library/papers/36656466 | PubMed |
| 35349164 | Interventions for reducing inflammation in familial Mediterranean fever. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/35349164 | PubMed |
| 34642922 | Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVID-19. | Cardiol J | 2023 | https://conductscience.org/library/papers/34642922 | PubMed |
| 34527926 | Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. | Arch Rheumatol | 2021 | https://conductscience.org/library/papers/34527926 | PubMed |
| 34527104 | M680I/M694V Heterozygous Mutation in Early Onset Familial Mediterranean Fever. | J Med Cases | 2021 | https://conductscience.org/library/papers/34527104 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4606353
GET https://conductscience.org/api/papers/v1/4606353/cited_by?page=2